No therapeutic advantage from didanosine (ddI) and hydroxyurea versus ddI alone in patients with HIV infection

AIDS. 1997 Aug;11(10):1299-300. doi: 10.1097/00002030-199710001-00006.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD4 Lymphocyte Count
  • Didanosine / administration & dosage
  • Didanosine / adverse effects
  • Didanosine / therapeutic use*
  • Drug Therapy, Combination
  • HIV Infections / drug therapy*
  • Humans
  • Hydroxyurea / administration & dosage
  • Hydroxyurea / therapeutic use*
  • RNA, Viral / blood
  • Treatment Outcome
  • Viremia / drug therapy
  • Zidovudine / therapeutic use

Substances

  • RNA, Viral
  • Zidovudine
  • Didanosine
  • Hydroxyurea